Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 TCR-T Therapy Targeting Mutated KRAS in Metastatic or Locally Advanced PDAC
2024-513900-32-00Phase 2Authorised
- Sponsor
- Anocca
- Start
- Jul 2025
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, HLA-matched TCR-T → TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of ANOC-001, ANOC-002 and ANOC-003 in pancreatic adenocarcinoma (PDAC), sponsored by Anocca. Primary endpoints: Incidence and nature of dose-limiting toxicities (DLTs) of ANOC-001, ANOC-002 and ANOC-003, Incidence, nature, and severity of adverse events (AEs) and 2 more. Planned start Jul 2025; status: authorised.
02
Drugs
ANOC-001ANOC-002ANOC-003
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-513900-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513900-32-00.